Thrombospondin-1 enhances human thyroid carcinoma cell invasion through urokinase activity

International Journal of Biochemistry and Cell Biology

Volumn 40, Issue 9, 2008, Pages 1890-1900

  Sid, Brice ^a   Langlois, Benoit ^a   Sartelet, Herve ^a   Bellon, Georges ^a   Dedieu, Stephane ^a   Martiny, Laurent ^a  

^a UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

Author keywords

Thrombospondin 1; Thyroid carcinoma; Tumor invasion; Urokinase

Indexed keywords

APROTININ; ENZYME INHIBITOR; METALLOPROTEINASE; THROMBOSPONDIN 1; UROKINASE;

ARTICLE; CANCER INVASION; CELL INVASION; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PROTEIN DEGRADATION; THYROID FOLLICULAR CARCINOMA; ZYMOGRAPHY;

ANIMALS; CELL LINE, TUMOR; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX METALLOPROTEINASE 2; MICE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROGNOSIS; SURVIVAL RATE; THROMBOSPONDIN 1; THYROID NEOPLASMS; URINARY PLASMINOGEN ACTIVATOR;

EID: 49949152493     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2008.01.023     Document Type: Article

References (43)

1. Albo D., Berger D.H., Wang T.N., Hu X., Rothman V., and Tuszynski G.P. Thrombospondin-1 and transforming growth factor-beta l promote breast tumor cell invasion through up-regulation of the plasminogen/plasmin system. Surgery 122 (1997) 493-499
2. Albo D., Rothman V.L., Roberts D.D., and Tuszynski G.P. Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor. Brain Journal of Cancer 83 (2000) 298-306
3. Albo D., and Tuszynski G.P. Thrombospondin-1 up-regulates tumor cell invasion through the urokinase plasminogen activator receptor in head and neck cancer cells. Journal of Surgery Research 120 (2004) 21-26
4. Arnoletti J.P., Albo D., Granick M.S., Solomon M.P., Castiglioni A., Rothman V.L., and Tuszynski G.P. Thrombospondin and transforming growth factor-beta 1 increase expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in human MDA-MB-231 breast cancer cells. Cancer 76 (1995) 998-1005
5. Bein K., and Simons M. Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity. The Journal of Biological Chemistry 275 (2000) 32167-32173
6. Bornstein P. Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1. Journal of Cell Biology 130 (1995) 503-506
7. Bornstein P., and Sage E.H. Matricellular proteins: extracellular modulators of cell function. Current Opinion in Cell Biology 14 (2002) 608-616
8. Bunone G., Vigneri P., Mariani L., Buto S., Collini P., Pilotti S., Pierotti M.A., and Bongarzone I. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. American Journal of Pathology 155 (1999) 1967-1976
9. Castle V., Varani J., Fligiel S., Prochownik E.V., and Dixit V. Antisense-mediated reduction in thrombospondin reverse the malignant phenotype of a human squamous carcinoma. Journal of Clinical Investigation 87 (1991) 1883-1888
10. Claisse D., Martiny L., Chaqour B., Wegrowski Y., Petitfrere E., Schneider C., Haye B., and Bellon G. Influence of transforming growth factor beta1 (TGF-beta1) on the behaviour of porcine thyroid epithelial cells in primary culture through thrombospondin-1 synthesis. Journal of Cell Science 112 (1999) 1405-1416
11. Czekay R.P., Kuemmel T.A., Orlando R.A., and Farquhar M.G. Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity. Molecular Biology of the Cell 12 (2001) 1467-1479
12. Demeure M.J., Damsky C.H., Elfman F., Goretzki P.E., Wong M.G., and Clark O.H. Invasion by cultured human follicular thyroid cancer correlates with increased beta 1 integrins and production of proteases. World Journal of Surgery 16 (1992) 770-776
13. Esemuede N., Lee T., Pierre-Paul D., Sumpio B.E., and Gahtan V. The role of thrombospondin-1 in human disease. Journal of Surgery Research 122 (2004) 135-142
14. Fears C.Y., Grammer J.R., Stewart J.E., Annis D.S., Mosher D.F., Bornstein P., and Gladson C.L. Low-density lipoprotein receptor-related protein contributes to the antiangiogenic activity of thrombospondin-2 in a murine glioma model. Cancer Research 65 (2005) 9338-9346
15. Ghoneim C., Soula-Rothhut M., Blanchevoye C., Martiny L., Antonicelli F., and Rothhut B. Activating transcription factor-1-mediated hepatocyte growth factor-induced down-regulation of thrombospondin-1 expression leads to thyroid cancer cell invasion. The Journal of Biological Chemistry 282 (2007) 15490-15497
16. Goretzki P.E., Frilling A., Simon D., and Roeher H.D. Growth regulation of normal thyroids and thyroid tumors in man. Recent Results Cancer Research 118 (1990) 48-63
17. Hawighorst T., Oura H., Streit M., Janes L., Nguyen L., Brown L.F., Oliver G., Jackson D.G., and Detmar M. Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice. Oncogene 21 (2002) 7945-7956
18. Hosokawa T., Muraishi A., Rothman V.L., Papale M., and Tuszynski G.P. The effect of thrombospondin on invasion of fibrin gels by human A549 lung carcinoma. Oncology Research 5 (1993) 183-189
19. Kim D.S., Franklyn J.A., Stratford A.L., Boelaert K., Watkinson J.C., Eggo M.C., and McCabe C.J. Pituitary tumor-transforming gene regulates multiple downstream angiogenic genes in thyroid cancer. Journal of Clinical Endocrinology and Metabolism 91 (2006) 1119-1128
20. Kraiem Z., and Korem S. Matrix metalloproteinases and the thyroid. Thyroid 10 (2000) 1061-1069
21. Lee T., Esemuede N., Sumpio B.E., and Gahtan V. Thrombospondin-1 induces matrix metalloproteinase-2 activation in vascular smooth muscle cells. Journal of Vascular Surgery 38 (2003) 147-154
22. Moon Y., Bottone F.G., McEntee M.F., and Eling T.E. Suppression of tumor cell invasion by cyclooxygenase inhibitors is mediated by thrombospondin-1 via the early growth response gene Egr-1. Molecular Cancer Therapy 4 (2005) 1551-1558
23. Nagayama Y., Shigematsu K., Namba H., Zeki K., Yamashita S., and Niwa M. Inhibition of angiogenesis and tumorigenesis, and induction of dormancy by p53 in a p53-null thyroid carcinoma cell line in vivo. Anticancer Research 20 (2000) 2723-2728
24. Patey M., Delemer B., Bellon G., Martiny L., Pluot M., and Haye B. Immunohistochemical study of thrombospondin and its receptors alpha root of beta 3 and CD36 in normal thyroid and in thyroid tumours. Journal of Clinical Pathology 52 (1999) 895-900
25. Rath G.M., Schneider C., Dedieu S., Rothhut B., Soula-Rothhut M., Ghoneim C., Sid B., Morjani H., El Btaouri H., and Martiny L. The C-terminal CD47/IAP-binding domain of thrombospondin-1 prevents camptothecin- and doxorubicin-induced apoptosis in human thyroid carcinoma cells. Biochimica et Biophysica Acta 1763 (2006) 1125-1134
26. Roberts D.D. Regulation of tumor growth and metastasis by thrombospondin-1. FASEB Journal 10 (1996) 1183-1191
27. Rofstad E.K., Henriksen K., Galappathi K., and Mathiesen B. Antiangiogenic treatment with thrombospondin-1 enhances primary tumor radiation response and prevents growth of dormant pulmonary micrometastases after curative radiation therapy in human melanoma xenografts. Cancer Research 63 (2003) 4055-4061
28. Scarpino S., Di Napoli A., Taraboletti G., Cancrini A., and Ruco L.P. Hepatocyte growth factor (HGF) downregulates thrombospondin 1 (TSP-1) expression in thyroid papillary carcinoma cells. Journal of Pathology 205 (2005) 50-56
29. Shimada H., Mori T., Takada A., Takada Y., Noda Y., Takai I., Kohda H., and Nishimura T. Use of chromogenic substrate S-2251 for determination of plasminogen activator in rat ovaries. Thrombosis and Haemostasis 46 (1981) 507-510
30. Sid B., Dedieu S., Delorme N., Sartelet H., Rath G.M., Bellon G., and Martiny L. Human thyroid carcinoma cell invasion is controlled by the low density lipoprotein receptor-related protein-mediated clearance of urokinase plasminogen activator. International Journal of Biochemistry and Cell Biology 38 (2006) 1729-1740
31. Sid B., Sartelet H., Bellon G., El Btaouri H., Rath G., Delorme N., Haye B., and Martiny L. Thrombospondin 1: a multifunctional protein implicated in the regulation of tumor growth. Critical Review in Oncology/Hematology 49 (2004) 245-258
32. Silverstein R.L., Harpel P.C., and Nachman R.L. Tissue plasminogen activator and urokinase enhance the binding of plasminogen to thrombospondin. The Journal of Biological Chemistry 261 (1986) 9959-9965
33. Silverstein R.L., Nachman R.L., Pannell R., Gurewich V., and Harpel P.C. Thrombospondin forms complexes with single-chain and two-chain forms of urokinase. The Journal of Biological Chemistry 265 (1990) 11289-11294
34. Smit J.W., van der Pluijm G., Romijn H.A., Lowik C.W., Morreau H., and Goslings B.M. Degradation of extracellular matrix by metastatic follicular thyroid carcinoma cell lines: role of the plasmin activation system. Thyroid 9 (1999) 913-919
35. Soula-Rothhut M., Coissard C., Sartelet H., Boudot C., Bellon G., Martiny L., and Rothhut B. The tumor suppressor PTEN inhibits EGF-induced TSP-1 and TIMP-1 expression in FTC-133 thyroid carcinoma cells. Experimental Cell Research 304 (2005) 187-201
36. Streit M., Riccardi L., Velasco P., Brown L.F., Hawighorst T., Bornstein P., and Detmar M. Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis. PNAS 96 (1999) 14888-14893
37. Sutton C.D., O'Byrne K., Goddard J.C., Marshall L.J., Jones L., Garcea G., Dennison A.R., Poston G., Lloyd D.M., and Berry D.P. Expression of thrombospondin-1 in resected colorectal liver metastases predicts poor prognosis. Clinical Cancer Research 11 (2005) 6567-6573
38. Tanaka K., Sonoo H., Kurebayashi J., Nomura T., Ohkubo S., Yamamoto Y., and Yamamoto S. Inhibition of infiltration and angiogenesis by thrombospondin-1 in papillary thyroid carcinoma. Clinical Cancer Research 8 (2002) 1125-1131
39. Taraboletti G., Morbidelli L., Donnini S., Parenti A., Granger H.J., Giavazzi R., and Ziche M. The heparin binding 25 kDa fragment of thrombospondin-1 promotes angiogenesis and modulates gelatinase and TIMP-2 production in endothelial cells. FASEB Journal 14 (2000) 1674-1676
40. Vailhé B., and Feige J.J. Thrombospondins as anti-angiogenic therapeutic agents. Current Pharmaceutical Design 9 (2003) 583-588
41. Wang T.N., Qian X.H., Granick M.S., Solomon M.P., Rothman V.L., Berger D.H., and Tuszynski G.P. Inhibition of breast cancer progression by an antibody to a thrombospondin-1 receptor. Surgery 120 (1996) 449-454
42. Wang T.N., Qian X.H., Granick M.S., Solomon M.P., Rothman V.L., Berger D.H., and Tuszynski G.P. Thrombospondin-1 (TSP-1) promotes the invasive properties of human breast cancer. Journal of Surgery Research 63 (1996) 39-43
43. Yee K.O., Streit M., Hawighorst T., Detmar M., and Lawler J. Expression of the type-1 repeats of thrombospondin-1 inhibits tumor growth through activation of transforming growth factor-beta. American Journal of Pathology 165 (2004) 541-552